Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133980 | 0.89 | ADORA1 (0.35) | ADORA2AADORA1ADORA2BMAPTHDAC1 | |
| SCHEMBL6134252 | 0.88 | ADORA2A (0.38) | ADORA2AADORA1ADORA2B | |
| SCHEMBL6133826 | 0.87 | CLK1 (0.36) | ADORA2AADORA1ADORA2BMAPT | |
| SCHEMBL6134855 | 0.87 | KDM5B (0.36) | ADORA2AKDM5BADORA1ADORA2B | |
| SCHEMBL6134078 | 0.87 | GFER (0.41) | ADORA2AADORA1MAPT | |
| SCHEMBL6134941 | 0.86 | CDC7 (0.38) | ADORA2AADORA1ADORA2BCDC7DBF4 | |
| SCHEMBL6134324 | 0.85 | ADORA1 (0.47) | ADORA2AADORA1ADORA2B | |
| SCHEMBL6133855 | 0.85 | ADORA2A (0.48) | ADORA2AADORA1MAPTHDAC1 | |
| SCHEMBL6135805 | 0.84 | ADORA1 (0.37) | ADORA2AADORA1ADORA2BMAPT | |
| SCHEMBL6133788 | 0.83 | ADORA1 (0.39) | ADORA2AADORA1METADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885KDM5B 2880/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.